Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study

Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies

(2014) Esther Bettiol et al.   Future Microbiology

Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data

(2014) Thomas P Van Boeckel et al.   LANCET INFECTIOUS DISEASES

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010

(2013) Stephen P. Hawser et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetics of ertapenem in burns patients

(2013) E. Dailly et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?

(2013) D. Sousa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model

(2013) T. Tangden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Carbapenem Therapy for Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli or Klebsiella pneumoniae: Implications of Ertapenem Susceptibility

(2012) Nan-Yao Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

(2012) Vicki L. Collins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

(2012) L. S. Tzouvelekis et al.   CLINICAL MICROBIOLOGY REVIEWS

Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002–2010

(2012) Chi-Chang Huang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum  -lactamases: a systematic review and meta-analysis

(2012) K. Z. Vardakas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae

(2011) Nan-Yao Lee et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence

(2011) David P. Nicolau et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis

(2011) Un-In Wu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Classification and regression trees

(2011) N. Speybroeck   International Journal of Public Health

Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy

(2009) Alexandre P Zavascki et al.   Expert Review of Anti-Infective Therapy

Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations

(2009) Olaf Burkhardt et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical significance of extended-spectrum β-lactamases

(2008) Jesús Rodríguez-Baño et al.   Expert Review of Anti-Infective Therapy

Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern

(2008) Johann DD Pitout et al.   LANCET INFECTIOUS DISEASES